Jazz Pharmaceuticals plc JAZZ
Composite 58/100; the shares have moved about 29% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 21/100 — a strong mark against it.
Momentum ranks 74/100 — a moderate point in its favour. Valuation ranks 70/100 — a moderate point in its favour. Quality ranks 63/100 — a moderate point in its favour.
Growth ranks 21/100 — a strong mark against it.
What the company does Jazz Pharmaceuticals plc discovers, develops, and commercializes treatments for rare diseases and oncology, including Xywav for narcolepsy, Epidiolex for seizures, and Zepzelca for small cell lung cancer.
Key financials Revenue grew 19% YoY, but net margin is 0.7% and ROE is 0.7%. Debt/Equity is 1.20 with net debt/EBITDA at 1.27 and interest coverage negative. Forward P/E is 10.85 vs trailing at 2538.70.
Stock health Sideravia scores Weak Quality (41.7) but rich Valuation (44.2) and strong Momentum (88.1). RSI(14) is 65.70; stock is -1.12% below its 52-week high.
Price vs fair value The stock trades at a discount of 131.20% versus our fair-value estimate and a discount of 3.30% versus the analyst 12-month target. - Analysts expect earnings growth next week (Zacks, 2026-07-27) - Peer Rhythm Pharmaceuticals expected to beat earnings (Zacks, 2026-07-28) - Momentum pillar score of 88.1 supports near-term positive sentiment
Looking forward Key pipeline catalysts include Phase 3 readouts for Zanidatamab (HER2-positive GEA/BTC) and Dordaviprone (H3 K27M glioma).
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.